Company
MindImmune Therapeutics
Also known as MindImmune Therapeutics, Inc
- Business model
- B2B
- Legal name
- MindImmune Therapeutics, Inc
Claim, correct or request removal
Record updated 28 September 2026
About
MindImmune has made a fundamental discovery that implicates the peripheral immune system in the pathology of Alzheimer’s disease and are developing a novel therapeutic antibody that blocks the immune attack on the brain.
Funding snapshot
- Total raised
- $21.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $15.2M2025-11-24
Funding rounds
- Round, 2025
- $15.2M2025-11-24, SEC form D sold, 15 investors
- Round, 2022
- $5.3M2022-01-25, SEC form D sold, 12 investors
- Round, 2019
- $750K2019-10-22, SEC form D sold, 8 investors
Loading relationship preview